All In Biotech

Free tool

FAERS Monitor: Mulpleta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210923 or its brand name (Mulpleta, Lusutrombopag). Reports on generic versions are filed under their own applications.

Reports

39

Serious

27

69% of reports

Hospitalization

7

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death3
  • drug ineffective3
  • nausea3
  • ascites2
  • diarrhoea2
  • headache2
  • hospitalisation2
  • mesenteric vein thrombosis2
  • pain2
  • pancytopenia2
  • portal vein thrombosis2
  • pulmonary embolism2
  • shock haemorrhagic2
  • acute hepatic failure1
  • arterial injury1

Reports by year received

View as table
YearReports
20187
201910
20207
20211
20227
20232
20243
20252

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,120 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mesenteric vein thrombosis21085.1280.91,215
arterial injury1723.7104.4180
portal vein thrombosis2334.186.6373
shock haemorrhagic2132.534.4146
acute hepatic failure139.55.79
ascites236.79.538
pancytopenia219.35.019
pulmonary embolism211.42.910
hospitalisation27.01.85
nausea32.00.71
death31.90.61
pain21.80.50
headache21.70.40
diarrhoea21.70.40
drug ineffective31.20.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.